Doležalová R, Haluzík M M, Bošanská L, Lacinová Z, Kasalová Z, Stulc T, Haluzík M
Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Physiol Res. 2007;56(6):741-748. doi: 10.33549/physiolres.931060. Epub 2006 Nov 6.
Thiazolidinediones are insulin-sensitizing drugs acting through peroxisome proliferator-activated receptor (PPAR)-gamma. The aim of our study was to evaluate the effect of 5-month treatment with PPAR-gamma agonist--rosiglitazone (4 mg/day), on the circulating markers of endothelial dysfunction and to evaluate the role of changes in endocrine function of adipose tissue in this process. Biochemical and metabolic parameters, circulating adiponectin, resistin, ICAM-1, VCAM-1, E-selectin, P-selectin, PAI-1, myeloperoxidase (MPO), and matrix metalloproteinase-9 (MMP-9) concentrations were assessed in 10 women with type 2 DM before and after rosiglitazone treatment and in a control group of healthy women. At baseline, diabetic group had significantly higher serum concentrations of glucose, glycated hemoglobin, V-CAM and PAI-1 compared to control group. Adiponectin levels tended to be lower in diabetic group, while resistin concentrations did not differ from control group. Rosiglitazone treatment improved diabetes compensation, significantly reduced VCAM-1, PAI-1 and E-selectin concentrations and increased adiponectin levels, while it did not affect serum resistin concentrations. Adiponectin concentrations at baseline were inversely related to E-selectin and MPO levels, this correlation disappeared after rosiglitazone treatment. We conclude that 5-month rosiglitazone treatment significantly reduced several markers of endothelial dysfunction. This effect could be at least in part attributable to marked increase of circulating adiponectin levels.
噻唑烷二酮类药物是通过过氧化物酶体增殖物激活受体（PPAR）-γ起作用的胰岛素增敏药物。我们研究的目的是评估PPAR-γ激动剂——罗格列酮（4毫克/天）进行5个月治疗对内皮功能障碍循环标志物的影响，并评估脂肪组织内分泌功能变化在此过程中的作用。在罗格列酮治疗前后，对10名2型糖尿病女性患者以及一组健康女性对照组进行了生化和代谢参数、循环脂联素、抵抗素、细胞间黏附分子-1（ICAM-1）、血管细胞黏附分子-1（VCAM-1）、E-选择素、P-选择素、纤溶酶原激活物抑制剂-1（PAI-1）、髓过氧化物酶（MPO）和基质金属蛋白酶-9（MMP-9）浓度的评估。在基线时，糖尿病组的血糖、糖化血红蛋白、V-CAM和PAI-1血清浓度显著高于对照组。糖尿病组脂联素水平倾向于较低，而抵抗素浓度与对照组无差异。罗格列酮治疗改善了糖尿病病情，显著降低了VCAM-1、PAI-1和E-选择素浓度，并提高了脂联素水平，而对血清抵抗素浓度没有影响。基线时脂联素浓度与E-选择素和MPO水平呈负相关，罗格列酮治疗后这种相关性消失。我们得出结论，5个月的罗格列酮治疗显著降低了几种内皮功能障碍标志物。这种作用至少部分归因于循环脂联素水平的显著升高。
